Access to Health

SouthViews No. 231, 29 November 2021

Waive IP Rights & Save Lives

By Srividhya Ragavan

In October of 2020, when India and South Africa proposed a waiver from certain provisions of the TRIPS agreement, it was meant to increase local manufacturing capacity in these countries. The waiver was proposed as a tool to kick-start prevention, containment and treatment of COVID-19. While there is an imminent need to meet a growing supply-demand gap for all medical products, COVID-19 related products are urgently required in poorer nations to contain the pandemic. The waiver has an additional role to play in the larger trade schema. In enabling vaccination of populations across the globe, the waiver would be critical to normalize global trade. The paper below captures the benefits of the waiver and compares it with the existing flexibilities under the trade regime, being compulsory licensing.

(more…)

Policy Brief 107, November 2021

The Doha Ministerial Declaration on TRIPS and Public Health on its Twentieth Anniversary

By Nirmalya Syam, Viviana Munoz, Carlos M. Correa and Vitor Ido

This Policy Brief reviews the role of the Doha Declaration on TRIPS and Public Health in the twenty years since its adoption. It finds that the Doha Declaration has contributed to advance the use of the TRIPS flexibilities to promote public health and should be considered an important subsequent agreement to the TRIPS Agreement, despite the continuing challenges for WTO members to implement the TRIPS flexibilities in full. This brief also analyses the extent to which the Paragraph 6 System that became an amendment of the TRIPS Agreement as a new article 31 bis, pursuant to the Doha Declaration, has facilitated access to medicines and vaccines for countries with none or insufficient pharmaceutical manufacturing capacity. It finds that the system to date has not lived up to its promise. The Policy Brief recommends that WTO members assess and identify the challenges for the full use of the TRIPS flexibilities to promote public health, and advances that supplementary tools will need to be designed to never again allow such inequity in access to life saving vaccines and treatments as in the present COVID-19 pandemic.

(more…)

Policy Brief 106, November 2021

Strengthening WHO for Future Health Emergencies while Battling COVID-19: Major Outcomes of the 2021 World Health Assembly

By Nirmalya Syam and Mirza Alas

The 74th World Health Assembly of the World Health Organization (WHO) took place in May 2021 in a time when developing countries had to confront a substantial surge in COVID-19 infections and fatalities, while continuing to face inadequate access to vaccines. Meanwhile, the majority of the global supplies were secured by a few rich countries, ignoring the pleas of the WHO Secretariat. However, even though discussions around the COVID-19 response and strengthening emergency preparedness and response dominated the Assembly, WHO Member States could not achieve any concrete outcome to addressing the question of equitable access to vaccines and other health technologies for COVID-19. In this context, this policy brief describes some of the major outcomes of the Assembly.

(more…)

Documento de Investigación 140, Noviembre de 2021

Del SIDA al COVID-19: La OMS ante las crisis sanitarias globales

Por Germán Velásquez

Este documento de investigación es una compilación de artículos de Germán Velásquez publicados por el “Monde Diplomatique” (ediciones francesa y española) entre el 2003 y el 2021. El autor analiza como la OMS enfrentó las grandes crisis sanitarias de los últimos 20 años. El SIDA y la llegada de los primeros antiretrovirales, la gripe H1N1 con el despilfarro del Oseltamivir (nombre de marca “Tamiflu”) y las vacunas que al final fueron destruidas en grandes cantidades, el ébola donde la OMS llegó con cuatro meses de atraso, la hepatitis C y los fármacos que podrían curarla pero fueron lanzados al mercado con precios inaccesibles y, actualmente, la pandemia devastadora del COVID-19 que ha demostrado una vez más la insoportable desigualdad en el acceso a la salud y a las vacunas y tratamientos, entre los países del Norte y los países del Sur.

El denominador común a todas estas crisis sanitarias mundiales ha sido la reacción de los países miembros de la OMS de querer reformar la Organización de tal manera que ésta pueda responder mejor a la crisis del momento. Este es exactamente el movimiento que ha desatado la COVID-19 y el tema y las negociaciones que probablemente nos ocuparán en los próximos años.

(more…)

Informe Sobre Políticas 96, Julio 2021

Precios justos para la cobertura sanitaria universal: El impacto de la judicialización de la salud

Por Silvina Andrea Bracamonte y José Luis Cassinerio

En el presente trabajo se describen las principales directrices y recomendaciones sobre políticas de precios para ayudar a los países a desarrollar estrategias efectivas, como herramientas para lograr el acceso equitativo a los productos sanitarios con precios asequibles, desechando el creciente fenómeno de la judicialización de la salud como vía adecuada para abordar con un enfoque sistémico esta problemática compleja.

(more…)

Submission on 3rd Intersessional Meeting for Dialogue and Cooperation on Human Rights & 2030 Agenda for SDGs,, January 2021

South Centre’s Submission to the 3rd Intersessional Meeting for Dialogue and Cooperation on Human Rights and the 2030 Agenda for Sustainable Development

Strengthening human rights for fighting inequalities and building back better

The COVID-19 pandemic has caused a global crisis without precedent in modern history. Its effects have not been felt equally among all countries as it has exacerbated the profound economic and social inequalities affecting the most vulnerable. In light of the lessons, we have learned – and are still learning – from the fight against COVID-19 pandemic, the 3rd Intersessional Meeting for Dialogue and Cooperation on Human Rights and the 2030 Agenda serves as a vital opportunity to understand the needs and realities of those who are still ‘left behind’.

(more…)

SouthViews No. 182, 11 July 2019

The most expensive drug in the history of the pharmaceutical industry

By Germán Velásquez

On May 27, 2019 the US FDA gave marketing authorization for Zolgensma gene therapy, from the Swiss firm Novartis. The price of the drug, administered in a single dose, is 2.125 million dollars, making it the most expensive drug in the history of the pharmaceutical industry. (more…)

SouthViews No. 180, 20 May 2019

Colombia’s Biogenerics Regulation A Preliminary Court Decision in favour of Public Health

By Carolina Gómez

The Council of State of Colombia’s recent ruling on the abbreviated pathway for marketing authorization of biogenerics is a valuable step towards acceptance and uptake of biogenerics, favoring public health, access and market competition.

In 2014, after several years of discussion and heated debate, Colombia issued a regulation for sanitary registration of biotechnological medicines, including biogenerics. The regulation explicitly included an abbreviated pathway for the registration of biogenerics, which allows for reduction or, in some cases, even waivers of comparative efficacy clinical trials. PK/PD and inumunogenicity studies are required. (more…)

SouthViews No. 178, 19 March 2019

South-South cooperation for confronting the neglected problem of snakebite envenoming: the role of Costa Rica

By Dr. Jose María Gutiérrez and Ambassador Elayne Whyte Gómez

As of 2018, the international community has a global framework to address the problem of snakebite envenomings, an acute problem that affects rural populations in tropical areas of the world, which mainly affects people from the most vulnerable sectors of the population and leaves significant negative consequences in millions of people around the world. This global framework was adopted by a resolution of the World Health Organization (WHO) at its 71st World Assembly on May 24, 2018, thus providing for a strong mandate to develop a comprehensive plan to address this health problem, work with affected countries, partners, stakeholders and industry, and develop a comprehensive approach that will allow countries to implement an effective response to this health issue.

(more…)

SouthViews No. 162, 2 February 2018

Menace of drug resistance growing

By Anthony D So

This week the Prince Mahidol Awards conference will bring a global spotlight to the threat of emerging infectious diseases. The growing challenge of antimicrobial resistance (AMR) will feature prominently in these discussions. The timing could not be better, but we urgently need to see more action on the part of the UN Interagency Coordination Group on AMR and key intergovernmental agencies gathering in Bangkok. (more…)

SouthViews No. 160, 19 January 2018

Heading off Global Action on Access to Medicines in 2018

By Dr. Jorge Bermudez and Dr. Viroj Tangcharoensathien

At the dawn of 2018, political and health leaders must seize the growing momentum and opportunities to tackle the protracted challenges of access to medicines that undermine efforts to save lives and improve health as committed under the Agenda 2030 SDG by all UN member states. (more…)

SouthViews No. 157, 9 December 2017

Action Needed to Avoid the End of Modern Medicine

By Martin Khor

As global health leaders warn that antibiotic resistance is leading to the end of modern medicine, the World Health Organization (WHO) issues guidelines to prohibit or restrict using antibiotics to feed animals reared for their meat. Urgent coordinated actions are needed to avoid the end of modern medicine. The author Martin Khor is the Executive Director of the South Centre. This article was also published by Inter Press Service (IPS) (more…)

0

Your Cart